This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here
HOME / NVAF / Overview
Choose ELIQUIS® for your patients with NVAF
ELIQUIS® (apixaban) – an oral, direct factor Xa inhibitor - is indicated for:
- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥II)1
Robust, clinical evidence for ELIQUIS in patients with NVAF
ARISTOTLE Clinical Trial
ELIQUIS demonstrated a superior risk reduction in stroke / systemic embolism with significantly less major bleeding vs. warfarin in patients with NVAF2
AUGUSTUS Clinical Trial
ELIQUIS was superior to VKA for major or CRNM bleeding, with significantly fewer deaths or hospitalisations, in patients with NVAF on a P2Y12 inhibitor after a recent ACS and/or PCI3*
Real-World Data
ELIQUIS was associated with superior reductions in the rates of stroke / systemic embolism AND major bleeding vs. warfarin in ARISTOTLE, now complemented by real-world evidence2,4
ELIQUIS (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery.1
Footnotes:
*There is limited experience of treatment with ELIQUIS at the recommended dose for NVAF patients when used in combination with antiplatelet agents in patients with ACS and / or undergoing PCI after haemostasis is achieved. ELIQUIS should be used with caution when co-administered with aspirin and / or P2Y12 inhibitors because these medicinal products typically increase the bleeding risk.1
ACS = Acute Coronary Syndrome DVT = Deep Vein Thrombosis NVAF = Non-Valvular Atrial Fibrillation NYHA = New York Heart Association PE = Pulmonary Embolism PCI = Percutaneous Coronary Intervention TIA = Transient Ischaemic Attack VKA = Vitamin K Antagonist
References:
- ELIQUIS® (apixaban) Summary of Product Characteristics. Available at www.medicines.ie.
- Granger CB et al. N Engl J Med 2011; 365: 981–992.
- Lopes RD et al. N Engl J Med 2019; 365: 883–891.
- Lip GH et al. Stroke. 2018; 49: 2933–2944.
Date of Preparation: September 2025 | Job Description: 432-IE-2500025